STOCK TITAN
  1. Home
  2. News
  3. BIIB

Biogen Inc - BIIB STOCK NEWS

Welcome to our dedicated news page for Biogen (Ticker: BIIB), a resource for investors and traders seeking the latest updates and insights on Biogen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biogen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biogen's position in the market.

News
Octave® Bioscience, Inc. Announces Real-World Study Using its Multimodal Precision Care Solution for Multiple Sclerosis Patient Management
Rhea-AI Summary
Octave Bioscience plans to conduct an observational study with Biogen, utilizing their Octave Solution to evaluate 150 MS patients at leading clinics. The study aims to provide insights into patients and their treatments, ultimately improving care. Octave's Solution includes measurement tools for disease activity, enhanced MRI analytics, and a digital clinical program. The study is expected to be conducted for 12 months starting Fall 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
none
-
News
Biogen Appoints Jane Grogan as Head of Research
Rhea-AI Summary
Biogen Inc. appoints Jane Grogan as Executive VP, Head of Research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.97%
Tags
management
-
News
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder
Rhea-AI Summary
Biogen and Sage Therapeutics announced that the FDA has approved ZURZUVAE (zuranolone) 50 mg for adults with postpartum depression (PPD). ZURZUVAE is the first and only oral, once-daily, 14-day treatment that can provide rapid improvements in depressive symptoms for women with PPD. The FDA issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for zuranolone in the treatment of adults with major depressive disorder (MDD).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial fda approval
News
Biogen to Acquire Reata Pharmaceuticals
Rhea-AI Summary
BIIB and RETA: Biogen to Acquire Reata Pharmaceuticals for $7.3 Billion, SKYCLARYS Approved for Friedreich’s Ataxia
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
acquisition
-
News
Eisai Presents Latest Analysis of Lecanemab’s Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer’s Association International Conference (AAIC) 2023
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
none
-
News
FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Rhea-AI Summary
Eisai and Biogen receive FDA approval for LEQEMBI as the first and only treatment to slow cognitive and functional decline in adults with Alzheimer’s disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.48%
Tags
none
News
New Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
Rhea-AI Summary
Biogen announces new data on SPINRAZA in the treatment of spinal muscular atrophy (SMA). Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma. Biogen also reports progress on the development of a novel device to enhance the patient treatment experience.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Alcyone Therapeutics Receives FDA IDE Approval to Initiate Clinical Study of the ThecaFlex DRxTM System for Administration of SPINRAZA® (nusinersen)
Rhea-AI Summary
Alcyone Therapeutics has received FDA approval to initiate a pivotal trial for its implantable medical device, ThecaFlex DRx System. The trial will evaluate the safety and performance of the device for the delivery of SPINRAZA in spinal muscular atrophy patients. The first stage of the trial is set to begin in summer 2023 with 10 patients, followed by enrollment of an additional 80 patients in a second stage starting in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
clinical trial
-
News
Biogen Announces Changes to Its Board of Directors
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.81%
Tags
management
News
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer's Disease
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock BIIB logo
Biogen Inc

Nasdaq:BIIB

BIIB Rankings

#398 Ranked by Market Cap
#3170 Ranked by Stock Gains
N/A Ranked by Dividends

BIIB Stock Data

28.37B
144.82M
0.69%
92.98%
2.44%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Cambridge

About BIIB

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili